Early MS drug test aims to stop brain damage before it starts
NCT ID NCT04466150
Summary
This study is testing whether starting a medication called ocrelizumab very early after MS symptoms first appear can change signs of ongoing inflammation in the fluid around the brain and spinal cord. Researchers will treat 30 newly diagnosed adults and measure specific markers in their spinal fluid over three years. The goal is to see if this early, strong treatment might lead to better long-term health for people with MS.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California San Francisco
San Francisco, California, 94158, United States
Conditions
Explore the condition pages connected to this study.